Better Health. Better Life.

Dr. Christopher Andrews M.D., MSc, FRCPC Joins the Board of M Pharmaceutical Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 14, 2015) - Dr. Christopher Andrews, M.D., MSc, FRCPC, a highly-respected Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN, is joining the Board of Directors of M Pharmaceutical Inc. (the "Company") (CSE:MQ).

Dr. Andrews, who specializes in stomach disorders and physiology, is the latest leadership asset to join the Company, which is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity or diabetes.

"We're delighted to have someone of Dr. Andrews' background and profile join our organization and help us advance our vision for biomedical technologies designed to improve the lives of those dealing with obesity and diabetes," said Dr. Martin Mintchev, the President & Chief Executive Officer of the Company. "His addition to our Board of Directors will help ensure that we make the most of our vision and strategic plan reflected in technologies such as the e-Mosquito wearable blood glucose monitor, the implantable gastro-intestinal neuro stimulators and the ingestible pseudobezoars."

Dr. Andrews is a Clinical Associate Professor at the University of Calgary. He has had advanced training in gastrointestinal motility and function at the Mayo Clinic, where he also obtained a Masters Degree in Clinical Health Research. Dr. Andrews also specializes in the development of novel diagnostic and therapeutic methods related to gut function. He went to McMaster Medical School, followed by residencies in Internal Medicine and Gastroenterology at the University of British Columbia and University of Calgary, respectively.

Dr. Andrews has won many awards, including a Young Investigator Award from the American Motility Society for his research on the effects of glucagon-like peptide-1 on gastric accommodation, and is currently the Canadian Association of Gastroenterology Visiting Clinical Professor. He has published over 50 peer-reviewed articles and has numerous teaching citations from the University of Calgary Medical School.

Dr. Mintchev also acknowledged the contributions of David Lane of Coquitlam, B.C. to the growth and development of the Company: "We're in a strong position to continue our growth and fulfil our vision thanks largely to the work of David Lane as our inaugural President of the Company. As he leaves the board, we wish him all the best in his new endeavours and thank him for his service."

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss; and (iii) gastrointestinal neuro-stimulators using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach.


This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito and the temporary pseudobezoars. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on and such factors as the Company failing to complete the commercialization of the eMosquito and the temporary pseudobezoars.


M Pharmaceutical Inc.
Investor Relations

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.